Christopher Anzalone, Arrowhead Pharmaceuticals CEO

Vi­vo Cap­i­tal pitch­es $60M to bring Ar­row­head­'s RNAi meds to Chi­na via joint ven­ture

Gen­er­al­ly speak­ing, any biotech hop­ing to have a pres­ence in Chi­na has a num­ber of op­tions.

One could out-li­cense its drugs to one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.